Literature DB >> 8905032

The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture.

M Cwikiel1, J Eskilsson, M Albertsson, L Stavenow.   

Abstract

BACKGROUND: Cardiotoxicity still remains an unexplained toxic manifestation of 5-fluorouracil (5-FU). Clinical and experimental data suggest that endothelium of coronary arteries could be involved in the pathophysiological mechanisms of the syndrome. In order to further explain 5-FU induced cardiotoxicity, we investigated the influence of this drug on endothelial cells (EC) in a cell culture model.
MATERIALS AND METHODS: The influence of 5-FU on EC, with respect to DNA synthesis, cell death and release of prostacyclin by endothelial cells (EC) was studied. For comparison, we tested methotrexate (MTX), an antimetabolite without cardiotoxic properties, in the same way. Human endothelial cell lines (HEC) and bovine endothelial cells (BEC) were incubated with increasing concentrations of 5-FU and MTX for 48 hours. (3H)thymidine incorporation, total cellular protein, loss of (3H)thymidine from prelabelled cells and 6-keto-prostaglandin F1 were measured.
RESULTS: DNA synthesis decreased significantly in both HEC and BEC, and the release of prostacyclin by BEC increased significantly when incubated with 5-FU. This effect was not seen with MTX.
CONCLUSION: The results indicate specific susceptibility of benign EC to 5-FU. Such susceptibility was confirmed by the release of prostacyclin by the BEC, indicating leakage secondary to EC injury.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8905032     DOI: 10.1093/oxfordjournals.annonc.a010723

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  21 in total

Review 1.  Approach to chemotherapy-associated thrombosis.

Authors:  Peter Oppelt; Anthony Betbadal; Lalitha Nayak
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

Review 2.  Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.

Authors:  Hui-Ming Chang; Rohit Moudgil; Tiziano Scarabelli; Tochukwu M Okwuosa; Edward T H Yeh
Journal:  J Am Coll Cardiol       Date:  2017-11-14       Impact factor: 24.094

Review 3.  Cardiotoxicity of the antiproliferative compound fluorouracil.

Authors:  K Becker; J F Erckenbrecht; D Häussinger; T Frieling
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

4.  Venous thromboembolism (VTE) and glioblastoma.

Authors:  Shlomit Yust-Katz; Jacob J Mandel; Jimin Wu; Ying Yuan; Courtney Webre; Tushar A Pawar; Harshad S Lhadha; Mark R Gilbert; Terri S Armstrong
Journal:  J Neurooncol       Date:  2015-05-19       Impact factor: 4.130

5.  Coronary vasospasm secondary to 5-Fluorouracil and its management: case report.

Authors:  Mustafa Yildirim; Cem Parlak; Cem Sezer; Ramazan Eryilmaz; Cetin Kaya; Mustafa Yildiz
Journal:  Eurasian J Med       Date:  2011-04

Review 6.  Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity.

Authors:  Umberto Campia; Ana Barac
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-07

Review 7.  New insights into cancer-associated thrombosis.

Authors:  Tarek Sousou; Alok A Khorana
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03       Impact factor: 8.311

Review 8.  Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.

Authors:  Michael E Layoun; Chanaka D Wickramasinghe; Maria V Peralta; Eric H Yang
Journal:  Curr Oncol Rep       Date:  2016-06       Impact factor: 5.075

9.  Acute coronary syndrome induced by oral capecitabine.

Authors:  Daniela Cardinale; Alessandro Colombo; Nicola Colombo
Journal:  Can J Cardiol       Date:  2006-03-01       Impact factor: 5.223

10.  5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1.

Authors:  Paola Altieri; Roberto Murialdo; Chiara Barisione; Edoardo Lazzarini; Silvano Garibaldi; Patrizia Fabbi; Clarissa Ruggeri; Silvia Borile; Federico Carbone; Andrea Armirotti; Marco Canepa; Alberto Ballestrero; Claudio Brunelli; Fabrizio Montecucco; Pietro Ameri; Paolo Spallarossa
Journal:  Br J Pharmacol       Date:  2017-02-22       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.